Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Phathom Pharmaceuticals, Inc. (United States)
Homepage:
phathompharma.com
Alternate names:
Phathom Pharmaceuticals,
Phathom Pharmaceuticals, Inc.
ROR:
04n7hp979
OpenAlex ID:
I4405267837
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial
2022
·
William D. Chey
, Francis Mégraud
, et al.
·
Gastroenterology
·
336
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial
2022
·
Loren Laine
, Kenneth DeVault
, et al.
·
Gastroenterology
·
176
Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe
2022
·
Francis Mégraud
, David Y. Graham
, et al.
·
The American Journal of Gastroenterology
·
103
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects
2022
·
Loren Laine
, Prateek Sharma
, et al.
·
The American Journal of Gastroenterology
·
93
The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan
2021
·
Darcy J. Mulford
, Eckhard Leifke
, et al.
·
Clinical Pharmacology in Drug Development
·
52
Diagnosis and treatment patterns among patients with newly diagnosed Helicobacter pylori infection in the United States 2016–2019
2023
·
Shailja Shah
, Katherine Cappell
, et al.
·
Scientific Reports
·
49
PDF
Randomised clinical trial: Efficacy and safety of on‐demand vonoprazan versus placebo for non‐erosive reflux disease
2023
·
Ronnie Fass
, Michael Vaezi
, et al.
·
Alimentary Pharmacology & Therapeutics
·
47
PDF
Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial
2024
·
Loren Laine
, Stuart Spechler
, et al.
·
Clinical Gastroenterology and Hepatology
·
42
Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure
2022
·
Shailja Shah
, Elizabeth Hubscher
, et al.
·
Expert Review of Gastroenterology & Hepatology
·
33
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure
2021
·
Carmelo Scarpignato
, Eckhard Leifke
, et al.
·
The Journal of Clinical Pharmacology
·
25
PDF
A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection
2023
·
Carmelo Scarpignato
, Colin W. Howden
, et al.
·
Alimentary Pharmacology & Therapeutics
·
20
PDF
Induction and maintenance of healing in erosive esophagitis in the United States
2022
·
Rena Yadlapati
, Elizabeth Hubscher
, et al.
·
Expert Review of Gastroenterology & Hepatology
·
19
Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis
2024
·
Colin W. Howden
, Philip Katz
, et al.
·
Alimentary Pharmacology & Therapeutics
·
18
PDF
Potassium-Competitive Acid Blocker and Proton Pump Inhibitor–Based Regimens for First-Line Helicobacter pylori Eradication: A Network Meta-Analysis
2022
·
Peter Malfertheiner
, Steven F. Moss
, et al.
·
Gastro Hep Advances
·
18
PDF
The Perils and Pitfalls of Esophageal Dysmotility in Idiopathic Pulmonary Fibrosis
2021
·
Ramsah Cheah
, Supphamat Chirnaksorn
, et al.
·
The American Journal of Gastroenterology
·
16
Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and Helicobacter pylori
2024
·
Carol M. Antequera
, Kimberly Orleck
, et al.
·
Postgraduate Medicine
·
14
Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling
2023
·
Darcy J. Mulford
, Diane Ramsden
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
·
14
PDF
Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of Helicobacter pylori infection
2023
·
Steven F. Moss
, William D. Chey
, et al.
·
Therapeutic Advances in Gastroenterology
·
14
PDF
Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates
2024
·
Colin W. Howden
, Carmelo Scarpignato
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
·
13
PDF
Comparison of Los Angeles Grades of Erosive Esophagitis Scored by Local Investigators vs Central Adjudicators in a Clinical Trial
2024
·
Stuart J. Spechler
, Loren Laine
, et al.
·
Clinical Gastroenterology and Hepatology
·
11
Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan
2023
·
Colin W. Howden
, Erin E. Cook
, et al.
·
Therapeutic Advances in Gastroenterology
·
8
PDF
Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients
2022
·
Michael F Vaezi
, Stephen Brunton
, et al.
·
BMJ Open Gastroenterology
·
7
PDF
S1382 Vonoprazan Dual and Triple Therapy for Helicobacter pylori Eradication
2021
·
William D. Chey
, Francis Mégraud
, et al.
·
The American Journal of Gastroenterology
·
7
Study of Acid-related Disorders: Real-world Physician and Patient Perspectives on Burden of Helicobacter pylori Infection
2022
·
Colin W. Howden
, Stuart J. Spechler
, et al.
·
Gastro Hep Advances
·
6
Healthcare costs among patients with newly diagnosed helicobacter pylori infection in the United States: a linked claims-EHR study
2023
·
Shailja Shah
, Katherine Cappell
, et al.
·
Journal of Medical Economics
·
5
PDF
Show more works
View as search
Works count:
41
Citation count:
2,472
Year
Topic
Type
